These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24003397)

  • 1. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors.
    Özkan ZG; Kuyumcu S; Balköse D; Ozkan B; Aksakal N; Yılmaz E; Sanlı Y; Türkmen C; Aral F; Adalet I
    Mol Imaging Radionucl Ther; 2013 Aug; 22(2):49-55. PubMed ID: 24003397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
    Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of
    Gabriel S; Garrigue P; Dahan L; Castinetti F; Sebag F; Baumstark K; Archange C; Jha A; Pacak K; Guillet B; Taïeb D
    Clin Endocrinol (Oxf); 2018 Aug; 89(2):155-163. PubMed ID: 29788534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of
    Hou G; Jiang Y; Li F; Cheng X
    Front Oncol; 2021; 11():762327. PubMed ID: 34692551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison of
    Liu Q; Zang J; Yang Y; Ling Q; Wu H; Wang P; Lu L; Zhu Z
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4386-4395. PubMed ID: 34146130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients.
    Torpy DJ; Chen CC; Mullen N; Doppman JL; Carrasquillo JA; Chrousos GP; Nieman LK
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1186-92. PubMed ID: 10199751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Impact of [
    Wannachalee T; Turcu AF; Bancos I; Habra MA; Avram AM; Chuang HH; Waguespack SG; Auchus RJ
    Clin Endocrinol (Oxf); 2019 Aug; 91(2):288-294. PubMed ID: 31066920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.
    Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M
    Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
    Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Acting Somatostatin Analog Therapy Differentially Alters
    Ayati N; Lee ST; Zakavi R; Pathmaraj K; Al-Qatawna L; Poon A; Scott AM
    J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 20. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.